Navigation Links
DALT GRADIENT MAKER,230V from GE Healthcare, formerly Amersham Biosciences

ProductsDALT GRADIENT MAKER,230V from GE Healthcare, formerly Amersham Biosciences
Company GE Healthcare, formerly Amersham Biosciences
Item DALT GRADIENT MAKER,230V
Price $2,206.00
Description DALT GRADIENT MAKER,230V, 1 EA.

Category: 2D DALT Systems.

Info GE Healthcare, formerly Amersham BiosciencesGE Healthcare, formerly Amersham Biosciences
800 Centennial Avenue
PO Box 1327
Piscataway, NJ 08855-1327
USA


For GE Healthcare contacts in other countries
please click here.


Call GE Healthcare, formerly Amersham Biosciences to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-461-9198
Customer Service: 732-457-8000
Fax Number: 732-235-2201
Web Site: http://www.gelifesciences.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. GRADIENT MAKER, 30 ML from GE Healthcare, formerly Amersham Biosciences
2. Taq DNA Polymerase (cloned) from GE Healthcare, formerly Amersham Biosciences
3. Taq DNA Polymerase (Thermus aquaticus) from GE Healthcare, formerly Amersham Biosciences
4. Taq DNA Polymerase (Thermus aquaticus) from GE Healthcare, formerly Amersham Biosciences
5. One-Phor-All Buffer PLUS from GE Healthcare, formerly Amersham Biosciences
6. Ready-To-Go T4 DNA Ligase from GE Healthcare, formerly Amersham Biosciences
7. CodeLink Activated Slides from GE Healthcare, formerly Amersham Biosciences
8. Cell Proliferation Kit from GE Healthcare, formerly Amersham Biosciences
9. Zebrafish Vitellogenin ELISA System from GE Healthcare, formerly Amersham Biosciences
10. Carp Vitellogenin ELISA System from GE Healthcare, formerly Amersham Biosciences
11. Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead from GE Healthcare, formerly Amersham Biosciences
... Clone/PAD: ZMD.473. Immunogen: Synthetic peptide ... the mouse junctophilin-2. Specificity: Specific ... Mouse (positive controls: mouse skeletal muscle ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: ...
TGF-beta 2 MAb (Clone 8607)...
UCP1/2/3 (FL-307)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products:
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... 2015 Fingerprint Cards (FPC) raises the ... will amount to at least 340 MSEK to that it ... increase in market growth and orders received the revenue guidance ... revenue for 2015 will exceed 1,500 MSEK to an updated ... MSEK. Due to receipt of orders of touch ...
(Date:6/11/2015)... Va. , June 11, 2015 ... technology, announced today that its IdentityX Mobile Authentication ... (Fast IDentity Online) Alliance is an industry consortium ... open standards for simpler, stronger authentication.  In order ... must pass a rigorous series of tests that ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... the UK have presented evidence that vigorous physical activity ... results were presented at the World Congress on Osteoporosis ... six-year olds participated in the study. Using advanced scanning ... structure of the femoral neck (hip) and thigh bone. ...
... Hinxton, 10 May 2010 The European Nucleotide Archive ... to become Europe,s primary access point to globally comprehensive ... available from the European Bioinformatics Institute (EMBL-EBI), a part ... DNA sequencing has led to previously unimaginable amounts of ...
... sources of renewable energy, but which ones should industry ... new study involving researchers from North Carolina State University ... burned. Their data and new computer models pave the ... maximize energy efficiency while minimizing environmental and human health ...
Cached Biology News:Enabling easy access to DNA sequence information 2Study paves way for new biofuels models, technologies 2
(Date:6/29/2015)... 29, 2015 According to a new ... by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), ... CRO) - Global Forecast to 2020", published by MarketsandMarkets, the ... 2020 from $107.56 Million in 2015, at a CAGR of ... and 67 F igures spread through 125 ...
(Date:6/29/2015)... Elsevier , a world-leading ... services, today announced the highlights of its journal Impact ... Citation Reports® (JCR) published by Thomson Reuters, Elsevier saw ... to 2014, ahead of the aggregate across other journals. ... 62 subject categories, up from 61 in 2013. ...
(Date:6/26/2015)... Lawrence, MA (PRWEB) , ... June 26, 2015 ... ... the U.S. Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... referred to as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. ...
(Date:6/26/2015)... June 23, 2015 ... addition of the "Global Cancer Biosimilars Market ... Market introduction of cancer biosimilar is required ... potential. Chemotherapeutic drugs have dominated the cancer segment ... been introduced in past few years. They are ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3